Key clinical point: Interleuken-6 and C-reactive protein levels are prognostic for checkpoint inhibition in patients with melanoma.
Major finding: Low baseline IL-6 was associated with lower overall survival in CheckMate 064 NIVO-IPI and IPI-NIVO groups (hazard ratios, 7.81 and 1.07).
Study details: Post hoc analyses of data for nearly 1,500 patients across CheckMate 064, 066, and 067.
Disclosures: Dr. Weber and Dr. Drake each reported relationships with numerous companies, including stock and other ownership interests and patents, consulting or advisory roles and/or receipt of honoraria, research funding to their respective institutions, and payment for travel, accommodations, and expenses.
Weber J et al. ASCO 2019, Abstract 100.